6L60 Stock Chart & Stats
€7.85
€0.10(2.45%)
At close: 4:00 PM EDT
€7.85
€0.10(2.45%)
Day’s Range― - ―
52-Week Range€4.04 - €9.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€437.41M
Enterprise Value€248.39M
Total Cash (Recent Filing)€142.66M
Total Debt (Recent Filing)€61.84M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Nov 10, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares Outstanding52,874,054
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.77
Price to Sales (P/S)6.53
P/FCF Ratio-3.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.59Price Target Upside47.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.03
Revenue Forecast (FY)€55.44M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin ImprovementImproving sales and gross margin indicate stronger product adoption and better unit economics. If sustained, this combination can expand the contribution from each Eversense system sold and provide operating leverage as the commercial base grows, although profitability has not yet been reached.
Differentiated Implantable CGM PlatformThe implantable sensor and wearable-transmitter design gives Eversense a distinct product architecture within diabetes monitoring. Continuous data and alerts for users and clinicians may support durable clinical utility and help differentiate the platform as adoption expands.
Greater European Commercial ControlTaking direct control of commercial operations across four European markets could deepen Senseonics’ regional capabilities and improve execution over time. The transactions expand its operational footprint and may give the company greater influence over Eversense market development.
Bears Say
Large And Widening LossesVery large losses show that operating expenses still materially exceed the company’s revenue base. Continued losses can delay the path to sustainable profitability, constrain internal investment capacity, and make future growth dependent on additional financial support.
Severe Negative Cash GenerationThe sharp deterioration in operating and free cash flow indicates that current operations are not self-funding despite improving revenue. Persistent cash consumption can reduce flexibility to invest in commercialization and increase reliance on external capital while losses remain high.
Historical Balance-Sheet InstabilityCurrent leverage appears manageable, but repeated periods of negative equity demonstrate a history of financial instability and significant capital needs. If losses and cash burn persist, the company may face renewed pressure to raise funds and preserve balance-sheet strength.
Senseonics Holdings News
6L60 FAQ
What was Senseonics Holdings Inc’s price range in the past 12 months?
Senseonics Holdings Inc lowest stock price was €4.04 and its highest was €9.00 in the past 12 months.
What is Senseonics Holdings Inc’s market cap?
Senseonics Holdings Inc’s market cap is €437.41M.
When is Senseonics Holdings Inc’s upcoming earnings report date?
Senseonics Holdings Inc’s upcoming earnings report date is Nov 10, 2026 which is in 28 days.
How were Senseonics Holdings Inc’s earnings last quarter?
Senseonics Holdings Inc released its earnings results on Aug 06, 2026. The company reported -€0.564 earnings per share for the quarter, missing the consensus estimate of -€0.549 by -€0.015.
Is Senseonics Holdings Inc overvalued?
According to Wall Street analysts Senseonics Holdings Inc’s price is currently Undervalued.
Does Senseonics Holdings Inc pay dividends?
Senseonics Holdings Inc does not currently pay dividends.
What is Senseonics Holdings Inc’s EPS estimate?
Senseonics Holdings Inc’s EPS estimate is -0.46.
How many shares outstanding does Senseonics Holdings Inc have?
Senseonics Holdings Inc has 52,874,054 shares outstanding.
What happened to Senseonics Holdings Inc’s price movement after its last earnings report?
Senseonics Holdings Inc reported an EPS of -€0.564 in its last earnings report, missing expectations of -€0.549. Following the earnings report the stock price went up 30.233%.
Which hedge fund is a major shareholder of Senseonics Holdings Inc?
Currently, no hedge funds are holding shares in DE:6L60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Senseonics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€11.59 (47.69% Upside)
€11.59 (47.69% Upside)
Blogger Sentiment
Bullish
DE:6L60 Sentiment 69%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth €111.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.00%
12-Months-Change
Fundamentals
Return on Equity
-165.83%
Trailing 12-Months
Asset Growth
17.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Senseonics Holdings Inc
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
6L60 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial momentum and validating financial results: Q1 revenue of $11.7M (up 85% YoY), a 58% gross margin, rapid DTC growth (~100% YoY) and successful U.S. commercial integration. Management raised 2026 revenue guidance to $60M–$64M (70%–82% growth) and advanced pipeline milestones (Gemini and Freedom) while adding substantial growth capital ($92M equity + expanded $140M credit facility with a $20M draw). Offsetting these positives are materially higher operating expenses and an expanded net loss driven by in‑house commercialization, significant planned cash burn ($110M–$120M for 2026), increased debt, and remaining execution risk in the European transition and competitive landscape. On balance, the highlights from stronger-than-expected top-line performance, margin expansion and financing to fund growth outweigh the near-term cost and cash challenges, but execution through the rest of 2026 will be key.View all DE:6L60 earnings summaries6L60 Stock 12 Month Forecast
Average Price Target
€11.59
▲(47.69% Upside)